AnaptysBio, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ANAB research report →
Companywww.anaptysbio.com
AnaptysBio, Inc. , a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation.
- CEO
- Daniel R. Faga
- IPO
- 2017
- Employees
- 136
- HQ
- San Diego, CA, US
Price Chart
Valuation
- Market Cap
- $2.61B
- P/E
- -64.86
- P/S
- 11.24
- P/B
- 136.31
- EV/EBITDA
- 49.51
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 116.42%
- Op Margin
- 17.56%
- Net Margin
- -11.53%
- ROE
- 442.91%
- ROIC
- 14.06%
Growth & Income
- Revenue
- $234.60M · 157.01%
- Net Income
- $-13,232,000 · 90.89%
- EPS
- $-0.46 · 91.02%
- Op Income
- $47.90M
- FCF YoY
- 114.45%
Performance & Tape
- 52W High
- $72.36
- 52W Low
- $11.40
- 50D MA
- $51.37
- 200D MA
- $31.69
- Beta
- 0.48
- Avg Volume
- 830.62K
Get TickerSpark's AI analysis on ANAB
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 11, 26 | Hughes Owen | other | 11,250 |
| May 11, 26 | Hughes Owen | other | 0 |
| May 11, 26 | Murphy Christopher M. | other | 25,765 |
| May 11, 26 | Murphy Christopher M. | other | 0 |
| Apr 27, 26 | GRAY SUSANNAH | other | 11,250 |
| Apr 20, 26 | Faga Daniel | sell | 11,000 |
| Apr 20, 26 | Orwin John A | other | 16,510 |
| Apr 20, 26 | Orwin John A | sell | 16,510 |
| Apr 20, 26 | Orwin John A | sell | 16,510 |
| Apr 20, 26 | Orwin John A | other | 16,510 |
Our ANAB Coverage
We haven't published any research on ANAB yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ANAB Report →